Paul F. Lizzul sold $101k of ANAB
Chief Medical Officer at ANAPTYSBIO, INC. 2,235 shares at an average of $45.11, traded Jan 7, 2026, filed Jan 8, 2026.
Score components
- +15RoleOfficer
- +10Trade size$101k at market
- 0Share of holdings soldSold 5.7% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +13.5%, 3m +56.5%, 6m +128.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001711462-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 6, 2026 | MOption exercise Common Stock | +6,145 | - | - | 39,448 | Jan 8, 2026 |
| Jan 7, 2026 | SOpen-market sale Common Stock | -2,235 | $45.11 | $101k | 37,213 | Jan 8, 2026 |
| Jan 6, 2026 | MOption exercise Restricted Stock Unitderivative | -6,145 | $0.00 | $0 | 6,145 | Jan 8, 2026 |
| Jan 6, 2026 | AGrant or award Restricted Stock Unitderivative | +21,400 | $0.00 | $0 | 21,400 | Jan 8, 2026 |
| Jan 6, 2026 | AGrant or award Stock Option (right to buy)derivative | +29,000 | $0.00 | $0 | 29,000 | Jan 8, 2026 |
Related signals
Other insiders at ANAPTYSBIO, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | ANAPTYSBIO, INC | Hollings Renton director | $249k 5,000 shares | -31% | |
| 58Moderate | ANAPTYSBIO, INC | John P. Schmid director | $1.2M 20,645 shares | -39% | |
| 58Moderate | ANAPTYSBIO, INC | Daniel Faga President, CEO | $1.1M 17,679 shares | -3% | |
| 9Weak | ANAPTYSBIO, INC | Eric J Loumeau CHIEF LEGAL OFFICER | $540k 10,000 shares | -44% | |
| 53Moderate | ANAPTYSBIO, INC | Magda Marquet director | $531k 11,000 shares | -53% | |
| 30Weak | ANAPTYSBIO, INC | Eric J Loumeau CHIEF LEGAL OFFICER | $99k 2,210 shares | -15% | |
| 37Weak | ANAPTYSBIO, INC | Dennis Mulroy CHIEF FINANCIAL OFFICER | $112k 2,515 shares | -10% | |
| 45Moderate | ANAPTYSBIO, INC | Daniel Faga President, CEO | $639k 14,281 shares | -3% | |
| 26Weak | ANAPTYSBIO, INC | Paul F. Lizzul Chief Medical Officer | $163k 3,650 shares | -8% | |
| 32Weak | ANAPTYSBIO, INC | Eric J Loumeau CHIEF LEGAL OFFICER | $439k 9,639 shares | -51% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.